Comments on: Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

Comments on: Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China https://9krapalm.com/innovent-announces-first-patient-dosed-in-pivotal-registrational-study-of-ibi363-tak-928-pd-1-il-2%ce%b1-biased-bispecific-fusion-protein-in-combination-with-bevacizumab-in-late-line-advanced-colore/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Thu, 06 Aug 2026 00:33:04 +0000 hourly 1 https://wordpress.org/?v=7.0.2